Literature DB >> 30616791

Comparative effectiveness of primary radiotherapy versus surgery in elderly patients with locally advanced oropharyngeal squamous cell carcinoma.

David J Sher1, Jingsheng Yan2, Andrew Day3, Baran D Sumer3, Nhat-Long Pham4, Saad Khan5, Hong Zhu2.   

Abstract

OBJECTIVES: To determine the comparative effectiveness of primary radiotherapy (RT) and primary surgery (PS) for locally advanced oropharyngeal squamous cell carcinoma (OPSCC).
MATERIALS AND METHODS: Eligible individuals were patients in the SEER-Medicare registry diagnosed with locally advanced OPSCC between 2000 and 2011. Patients were categorized as receiving either primary RT ± chemotherapy, or PS ± adjuvant RT or chemoradiotherapy (CRT). Overall survival (OS) was analyzed using Cox multivariable analysis (MVA). Risks of gastrostomy dependence (GD), esophageal stricture (ES), and osteoradionecrosis (ORN) were analyzed using logistic regression.
RESULTS: A total of 2754 patients (69% RT, 31% PS) were included in this cohort, with a median age of 72 years. Patients treated with RT, CRT and PS experienced 3-year OS outcomes of 36.1%, 52.8%, and 54.9%, respectively (p < 0.001). Increasing age, unmarried status, increasing comorbidity, lower income, base of tongue (BOT) site, higher stage, no prior PET, and RT alone (but not CRT) were associated with inferior OS. Independent predictors of GD at 6 months included black race, BOT site, advanced stage, and CRT. The risks of ORN and stricture were not associated with treatment modality. Concurrent chemotherapy improved OS with definitive RT but had no impact in adjuvant RT. Only cisplatin- and taxane-containing regimens improved OS, but all concurrent agents, including cetuximab, significantly worsened GD.
CONCLUSION: Local therapy decisions for locally advanced OPSCC must be individualized, with CRT increasing acute and chronic GD. The differential survival impact of concurrent chemotherapy in the definitive and adjuvant setting may be a consideration in decision-making.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Chemoradiotherapy; Combined-modality therapy; Oropharynx cancer; SEER-Medicare

Mesh:

Substances:

Year:  2018        PMID: 30616791     DOI: 10.1016/j.oraloncology.2018.11.004

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  8 in total

1.  NTF2 Upregulation in HNSCC: a Predictive Marker and Potential Therapeutic Target Associated With Immune Infiltration.

Authors:  Guangxu Xuan; Xin Zhang; Min Zhang; Minghang Yu; Yujie Zhou; Xiaosong He; Xiaopeng Hu; Xi Wang; Liangfa Liu
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

2.  TRIM24 Expression as an Independent Biomarker for Prognosis and Tumor Recurrence in HNSCC.

Authors:  Luise Klapper; Christian Idel; Patrick Kuppler; Tobias Jagomast; Amelie von Bernuth; Karl-Ludwig Bruchhage; Dirk Rades; Anne Offermann; Jutta Kirfel; Sven Perner; Julika Ribbat-Idel
Journal:  J Pers Med       Date:  2022-06-17

3.  Prognostic Factors Predict Oncological Outcome in Older Patients With Head and Neck Cancer Undergoing Chemoradiation Treatment.

Authors:  Carmen Stromberger; Berna Yedikat; Annekatrin Coordes; Ingeborg Tinhofer; Goda Kalinauskaite; Volker Budach; Sebastian Zschaeck; Jan-Dirk Raguse; Grzegorz Kofla; Max Heiland; Aksana Stsefanenka; Benedicta Beck-Broichsitter; Steffen Dommerich; Carolin Senger; Marcus Beck
Journal:  Front Oncol       Date:  2021-02-23       Impact factor: 6.244

4.  EVI1 as a Marker for Lymph Node Metastasis in HNSCC.

Authors:  Christian Idel; Julika Ribbat-Idel; Patrick Kuppler; Rosemarie Krupar; Anne Offermann; Wenzel Vogel; Dirk Rades; Jutta Kirfel; Barbara Wollenberg; Sven Perner
Journal:  Int J Mol Sci       Date:  2020-01-28       Impact factor: 5.923

5.  Immunologic "Cold" Squamous Cell Carcinomas of the Head and Neck Are Associated With an Unfavorable Prognosis.

Authors:  Julika Ribbat-Idel; Sven Perner; Patrick Kuppler; Luise Klapper; Rosemarie Krupar; Christian Watermann; Finn-Ole Paulsen; Anne Offermann; Karl-Ludwig Bruchhage; Barbara Wollenberg; Christian Idel
Journal:  Front Med (Lausanne)       Date:  2021-01-27

6.  Association of Primary Treatment Modality for Advanced-Stage Oropharyngeal Squamous Cell Carcinoma With Survival Outcomes.

Authors:  Mu-Hung Tsai; Yung-Jen Cheng; Tzu-Hui Pao; Wei-Ting Hsueh; Helen H W Chen; Yuan-Hua Wu
Journal:  JAMA Netw Open       Date:  2021-06-01

7.  NR2F6 as a Prognostic Biomarker in HNSCC.

Authors:  Luise Klapper; Julika Ribbat-Idel; Patrick Kuppler; Finn-Ole Paulsen; Karl-Ludwig Bruchhage; Dirk Rades; Anne Offermann; Jutta Kirfel; Barbara Wollenberg; Christian Idel; Sven Perner
Journal:  Int J Mol Sci       Date:  2020-08-01       Impact factor: 5.923

8.  CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC.

Authors:  Finn-Ole Paulsen; Christian Idel; Julika Ribbat-Idel; Patrick Kuppler; Luise Klapper; Dirk Rades; Karl-Ludwig Bruchhage; Barbara Wollenberg; Johannes Brägelmann; Sven Perner; Anne Offermann
Journal:  Int J Mol Sci       Date:  2020-07-31       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.